FDA Approves Vibativ (Telavancin) For Bacterial Pneumonia

Vibativ (telavancin) has been approved by the FDA to treat HABP/VABP (hospital-acquired ventilator-associated bacterial pneumonia) caused by Staphylococcus aureus. The FDA (Food and Drug Administration) added that telavancin should only be used when other treatments are not appropriate. Telavancin is a bactericidal lipoglycopeptide for use in MRSA (Methicillin-resistant Staphylococcus aureus) or other Gram-positive infections. It is a semi-synthetic derivative of vancomycin. The FDA approved telavancin in September 2009 for complicated skin and skin structure infections...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: MRSA / Drug Resistance Source Type: news